Clinical trials: Childhood Neoplasm
Colorectal Cancer
A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.
The purpose of this study is to determine the maximum tolerated dose (which will be the dose recommended for a Phase 2 study), safety, tolerability and pharmacokinetic profile (study of movement of the drug within the body…
- Trial name
- NCT02726334
- Testing
- BNC101 Solution for Infusion, BNC101 in combination with FOLFIRI
- Where
- 4 sites in Australia
- Volunteers
- 22 people
- Sponsor
- Bionomics Limited
Uterine Cervical Neoplasm, Dietary Modification
Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients
In Mexico, cervical cancer (CC) ranks second in incidence and mortality among women. The National Institute of Cancer in Mexico (lNCan) receives annually about 500 patients with CC, 80% of which are diagnosed with locally…
- Conditions
- Uterine Cervical Neoplasm, Dietary Modification, Radiation Toxicity, Gastrointestinal Complication
- Trial name
- NCT03100409
- Testing
- Dietary modification
- Where
- Mexico
- Volunteers
- 137 people
- Sponsor
- National Institute of Cancerología
Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
- Trial name
- NCT00054899
- Testing
- EP2101
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Epimmune
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
This study is a pilot clinical imaging trial of a prospective, head-to-head comparison of 18F-Fibroblast Activation Protein Inhibitor (FAPI)-74 PET/CT versus standard-of-care 18F-Fluorodeoxyglucose (FDG) PET/CT in 15 patients…
- Trial name
- NCT07285993
- Testing
- 18F-FAPI-74, 18F-FDG, PET/CT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Randy Yeh
Unresectable Metastatic Colorectal Cancer
OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer
Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
- Trial name
- VELVET (NCT01802684)
- Testing
- aflibercept
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreas Neoplasm
Usefulness of 3D Digital Reconstruction in the Imaging Diagnosis of Pancreatic Tumors
Reconstruction using 3D virtual models has brought about a revolution in diagnostic imaging and its use is increasingly widespread.
- Trial name
- NCT04783844
- Testing
- Virtual modelization.
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Virgen de la Arrixaca
Locally Advanced Breast Cancer, Breast Cancer
Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca
Women with breast cancer undergo treatments that decrease the chance of recurrence of cancer, but are associated with several side effects, including declines in memory and attention and other thinking abilities.
- Trial name
- Cyto-Cog (NCT00756132)
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Recurrent Head and Neck Cancer, Head and Neck Cancer
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
- Trial name
- NCT03691714
- Testing
- Durvalumab, Cetuximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Cincinnati
Colorectal Cancer, Colorectal Neoplasm
A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population
to determine screening value of stool-based SDC2 DNA methylation test for advanced colorectal neoplasia in the asymptomatic Chinese community population.
- Conditions
- Colorectal Cancer, Colorectal Neoplasm, Advanced Adenoma, Adenoma
- Trial name
- NCT04786704
- Testing
- Stool-based SDC2 DNA methylation test, quantitative Fecal immunochemical test
- Where
- China
- Volunteers
- 12,106 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Lymphoma
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and vinorelbine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00070304
- Testing
- filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
- Where
- 123 sites in United States, Australia and 3 more
- Volunteers
- 33 people
- Sponsor
- Children's Oncology Group
Lymphoblastic Lymphoma, Childhood
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Primary objectives: Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including…
- Trial name
- LBL 2018 (NCT04043494)
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- 228 sites in Austria, Belgium and 19 more
- Volunteers
- 683 people
- Sponsor
- University Hospital Muenster
Neoplasm of Lateral Wall of Urinary Bladder
Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors
This is a single-center, prospective, randomized, controlled trial comparing two established transurethral electrical resection methods of urinary bladder tumors regarding their risk of stimulating the obturator nerve.
- Trial name
- NCT01446822
- Testing
- Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius), Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Daniel Stephan Engeler
Brain Cancer
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples
To look for patterns of polymorphisms in DNA repair in both germline and tumor cells samples.
- Trial name
- NCT01650922
- Testing
- phlebotomy, biopsy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Background: Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor
- Trial name
- NCT03493945
- Testing
- M7824, N-803, MVA-BN-Brachyury
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Carcinoma, Adenocarcinoma
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.
- Conditions
- Head and Neck Carcinoma, Adenocarcinoma, Recurrent Disease, Distantly Metastatic Malignant Neoplasm
- Trial name
- NCT03591666
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Myelofibrosis, Primary Myelofibrosis
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551053
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 17 more
- Volunteers
- 177 people
- Sponsor
- Incyte Corporation
Non Small Cell Lung Cancer, Metastatic
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
The primary objective of this study is to establish the objective response rate (complete response + partial response) following treatment with VELCADE in combination with cisplatin plus gemcitabine in patients with locally…
- Trial name
- NCT01633645
- Testing
- Bortezomib, Gemcitabine, Cisplatin
- Where
- 5 sites in Greece
- Volunteers
- 53 people
- Sponsor
- University Hospital of Crete
Anal Neoplasm
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
This is a phase 2, open-label efficacy study of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) in adult men and women who are human immunodeficiency virus (HIV) negative with histologically…
- Trial name
- NCT03499795
- Testing
- VGX-3100, CELLECTRA™ 5PSP
- Where
- 3 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Inovio Pharmaceuticals
Prostate Cancer
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
This clinical study will evaluate the role of combination therapy of docetaxel followed by Provenge for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or…
- Trial name
- NCT02793765
- Testing
- Docetaxel, Sipuleucel-T
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Solid Tumor
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
The purpose of this study is to determine whether cytoreduction of bulky metastatic disease using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In patients who have exhausted SoC treatment…
- Trial name
- NCT06416436
- Testing
- Atezolizumab, Stereotactic Ablative Radiotherapy (SBRT)
- Where
- United States
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.